Cabaletta Bio (CABA) shares extended gains in recent premarket activity Friday after the company said it anticipates a 2027 biologics license application submission on a proposed registrational cohort design for a trial of resecabtagene autoleucel to treat myositis.
"Based on the minutes from our recent [Food and Drug Administration] meeting, we are proceeding with a registrational study design that includes two independent, subtype specific cohorts, each with approximately 15 patients and a primary endpoint within 26 weeks of rese-cel infusion," Chief Medical Officer David Chang said.
The company said the FDA granted regenerative medicine advanced therapy designation to rese-cel to treat myositis, a disabling, multi-system autoimmune disease.
Cabaletta also said it had cash and cash equivalents of $131.8 million as of March 31, expected to fund operating plan into H1 2026.
The company's shares closed 39% higher Thursday and were up 18% pre-bell Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.